Conference Coverage

Marijuana for migraine? Some tentative evidence


 

FROM AHS 2020

Medical marijuana may have promise for managing headache pain, according to results from a small study conducted at the Jefferson Headache Center at Thomas Jefferson University. The researchers found general satisfaction with medical marijuana, more frequent use as an abortive medication rather than a preventative, and more than two-thirds using the inhaled form rather than oral.

Claire Ceriani, MD, a headache fellow at Thomas Jefferson University in Philadelphia.

Dr. Claire Ceriani

Many patients ask about medical marijuana, but there is relatively little data on its effects on headache. Studies are generally retrospective, and often focus on marijuana use for general pain, with subset analyses looking at headache, according to coauthor Claire Ceriani, MD, who is a headache fellow at Jefferson. “A lot of patients are interested in medical marijuana but don’t know how to integrate it into the therapy plan they already have – whether it should be just to treat bad headaches when they happen, or is it meant to be a preventive medicine they use every day? We have some data out there that it can be helpful, but not a lot of specific information to guide your recommendations,” said Dr. Ceriani in an interview.

Although the research is far from a final word on the subject, it did have some take-home messages, said Dr. Ceriani. “Most people seem to find it effective as an abortive medication that might be able to take the place of some of the prescription medications that they were previously using,” she said.

The study was part of the virtual annual meeting of the American Headache Society.

An effective abortive therapy?

The study began shortly after the Jefferson Headache Center became certified to offer medical marijuana around the beginning of 2019. “We wanted to start keeping track of these patients from the get-go so we’d be able to learn as much as possible from them and help guide the recommendations we give to patients in the future,” said Dr. Ceriani.

The study included 48 patients with migraine or other types of chronic headache who received medical marijuana treatment between January and September 2019. After collecting baseline information from medical records and questionnaires filled out at marijuana treatment initiation, the researchers followed up periodically with telephone questionnaires to assess treatment response and side effects. About half of the participants (56.3%) reported daily headache. 14.6% had posttraumatic headache, 10.4% new daily persistent headache, and 4.2% tension-type headache. Additional symptoms were common, including anxiety (72.9%) and insomnia (62.5%).

A total of 28 subjects completed a follow-up questionnaire over the phone. Out of the 28 participants , 3 had stopped using marijuana. Of 25 subjects who continued use, 71.4% used it two or more times per week, and 25.0% used it every day. Among participants, 50% used a THC-dominant strain of marijuana. Overall, 71.4% used an inhaled form.

Side effects included dry mouth/throat (46.4%), dry/red eyes (35.7%), fatigue/lethargy (35.7%), and increased appetite (35.7%).

Before starting on marijuana, 46.4% of the subjects used abortive medications at least 10 days per month. After starting marijuana treatment, the rate dropped to 25.0%. Marijuana use was associated with improvements in anxiety: 57.1% who had anxiety reported improvement with marijuana use, as did 78.6% with insomnia. On a scale of 10, the average rating of marijuana’s usefulness was 5.9, and 17.9% rated it as 10.

Pages

Recommended Reading

Galcanezumab looks promising for treatment-resistant migraine
Migraine ICYMI
Population study supports migraine–dementia link
Migraine ICYMI
Few patients with migraine clear barriers to optimal care
Migraine ICYMI
Persistent posttraumatic headache risk factors confirmed
Migraine ICYMI
Intranasal DHE shows promise in migraine
Migraine ICYMI
CGRPs in real world: Similar efficacy, more AEs
Migraine ICYMI
NSAID/triptan combination improves treatment-resistant migraine
Migraine ICYMI
Commonalities challenge the threshold of high-frequency episodic and low-frequency chronic migraine
Migraine ICYMI
Adding CGRP to Botox is safe and effective for migraine prevention
Migraine ICYMI
Headache may predict clinical evolution of COVID-19
Migraine ICYMI